CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort
ContributorsJünger, Stephanie T; Andreiuolo, Felipe; Mynarek, Martin; Wohlers, Inken; Rahmann, Sven; Klein-Hitpass, Ludger; Dörner, Evelyn; Zur Mühlen, Anja; Velez-Char, Natalia; von Hoff, Katja; Warmuth-Metz, Monika; Kortmann, Rolf-Dieter; Timmermann, Beate; Von Bueren, André
Published inActa neuropathologica, vol. 140, no. 3, p. 405-407
Publication date2020-09
First online date2020-06-08
Keywords
- Cohort Studies
- Cyclin-Dependent Kinase Inhibitor p16 / deficiency
- Cyclin-Dependent Kinase Inhibitor p16 / metabolism
- Ependymoma / diagnosis
- Ependymoma / drug therapy
- Ependymoma / metabolism
- Ependymoma / pathology
- Humans
- Prognosis
- Supratentorial Neoplasms / metabolism
- Supratentorial Neoplasms / pathology
- Transcription Factor RelA / metabolism
Research group
Citation (ISO format)
JÜNGER, Stephanie T et al. <i>CDKN2A</i> deletion in supratentorial ependymoma with <i>RELA</i> alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort. In: Acta neuropathologica, 2020, vol. 140, n° 3, p. 405–407. doi: 10.1007/s00401-020-02169-z
Main files (1)
Article (Published version)
Identifiers
- PID : unige:157308
- DOI : 10.1007/s00401-020-02169-z
- PMID : 32514758
- PMCID : PMC7423858
ISSN of the journal0001-6322
